FFRangio delivers highly accurate multi-vessel FFR without the need for an invasive pressure wire or hyperemic stimulus, making objective FFR guidance practical for more patients.
FAME study: FFR-guided PCI improves outcomes and saves cost compared to angiography-guided PCI.
Reduction in stents per patient*
Relative Reduction in 1-year clinical events*
Reduction in costs at 1-year**
Learn more about FFRangio insights discussed at TCT.watch the tct symposium
“FFRangio has the potential to eventually replace wire-based FFR measurement and substantially increase physiological coronary lesion assessment in the catheterization laboratory, thereby leading to improved patient outcomes”View Clinical Studies
FAST-FFR Trial: Fearon WF, et al. Circ. September 2018. 10.1161/CIRCULATIONAHA.118.037350.
San Francisco, CARoom 203,
The CathWorks FFRangio™ System has received United States 510(k) clearance, Europe CE approval, Israel Amar approval, and Japan PMDA approval.
*Tonino et al. N Engl J Med. January 15, 2009; 360:213-224;
**Fearon et al. Circulation. 2010;122:2545-2550;